Antibody Market Dataset: Top 100 Antibodies in 2025 | 2026 Analysis

CiteAb compiles this final ranking by scoring antibody reagents based on their citation share in publications over the past year. The list covers monoclonal, polyclonal and recombinant antibodies. The ranking prioritizes citation count — a metric measuring how frequently a product appears in peer-reviewed published researchCiteAb.

Most Highly Cited Research Antibodies：

1. Secondary antibodies and housekeeping reference antibodies hold prominent positions within the Top 100 list. This is hardly surprising, given their widespread use as fundamental laboratory tools such as secondary antibodies.

2. Recombinant and monoclonal antibodies maintain stable market shares at the top tier. Breakdown of the Top 100 ranking shows approximately 40% monoclonal antibodies and one-quarter recombinant antibodies, nearly identical to last year’s proportions. When focusing on the leading antibodies within the list, nearly 70% are monoclonal antibodies and 38% are recombinant antibodies.

3. Targets involved in cell signaling and immunology receive the highest citation volume. Focusing on primary antibody targets, we observe clear trends: cell signaling pathways show broad coverage, with deeper penetration for the Akt/mTOR pathway. New additions to the Top 100 immunology targets include CD4 and TIM3 antibodies; Iba1 (a marker linked to neuroinflammation) also enters the ranking for the first time.

Notably, EnkiLife offers more than 19,000 antibody products, covering secondary antibodies, housekeeping reference antibodies, and the nearly 70% monoclonal antibodies featured on this ranking.